Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.70 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | CTSC | P53634 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | F2R | P25116 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | BCR | P11274 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774227 | 0.89 | PTGES (0.78) | PTGESKCNK3KCNK9MEN1KMT2A | |
| SCHEMBL3775210 | 0.85 | PTGES (0.50) | PTGESMEN1KMT2APTGS1CTSC | |
| SCHEMBL3771680 | 0.83 | PTGES (0.81) | PTGESKCNK3KCNK9MEN1KMT2A | |
| SCHEMBL3764443 | 0.83 | PTGES (1.00) | PTGESKCNK3KCNK9MEN1KMT2A | |
| SCHEMBL3771936 | 0.82 | PTGES (0.79) | PTGESKCNK3KCNK9MEN1KMT2A | |
| SCHEMBL3771077 | 0.82 | PTGES (0.79) | PTGESKCNK3KCNK9MEN1KMT2A | |
| SCHEMBL3771368 | 0.82 | PTGES (0.79) | PTGESKCNK3KCNK9MEN1KMT2A | |
| SCHEMBL3776618 | 0.82 | PTGES (0.79) | PTGESKCNK3KCNK9MEN1KMT2A | |
| SCHEMBL3775385 | 0.79 | PTGES (0.75) | PTGESKCNK3KCNK9MEN1KMT2A | |
| SCHEMBL3779837 | 0.76 | PTGES (0.69) | PTGESKCNK3KCNK9PTGS1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | PTGES 54/4885KCNK3 1692/4885KCNK9 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.